Table 1.
Summary of treatments in LCNEC.
| Study | Line of therapy | Regimen | ORR | mPFS | mOS |
|---|---|---|---|---|---|
| GFPC 0302 study Prospective phase II |
Frontline | Cisplatin + Etoposide | 34% | 5 m | 8 m |
| Niho et al. Japan. Prospective phase II |
Frontline | Cisplatin + Irinotecan | 46.7% | 5.8 m | 12.6 m |
| Christopoulos et al. German Prospective phase II |
Frontline | Everolimus with paclitaxel and carboplatin | 45% | 4.4 m | 9.9 m |
| Fujiwara et al. Retrospective review |
Frontline | Cisplatin + Irinotecan Paclitaxel-based |
55.6% 71% |
4.1 m | 10.3 m |
| Sun et al. Retrospective review |
Frontline | Platinum + Etoposide/ Platinum + Taxane/gemcitabine/pemetrexed/vinorelbine/EGFR TKI |
73% 50% |
6.1 m 4.9 m |
16.5 m 9.2 m |
| Yoshida et al. Retrospective review |
Second line | Amrubicin | 27.7% | 3.1 m | 5.1 m |
| Sherman et al. Retrospective review |
10% 1st line 80% 2nd line 10% beyond 2nd line |
Checkpoint inhibitor | 33% | 4.2 m | 11.8 m |